Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix Global Insights. Exton, PA., November 03, 2025 – Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological conditions—Amyotrophic Lateral Sclerosis (ALS), […]
Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV) leading prescribing. Exton, PA., October 29, 2025 – Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a comprehensive view of real-world management trends and competitive dynamics […]
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation. EXTON, Pa, May 15, 2025 — The treatment landscape for generalized myasthenia gravis (gMG) has entered a new era of therapeutic innovation. Since 2022, seven novel targeted biologics have launched, with a robust pipeline poised […]
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap on out-of-pocket (OOP) prescription drug […]
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities, including the reduction […]
Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologists
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by Spherix Global Insights (Exton, PA). Researchers found that general neurologists treat approximately 25% of people with epilepsy who have developed refractory epilepsy, constituting a significant proportion of the overall patient […]
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education efforts, according to Spherix Global Insights. EXTON, PA., July 8, 2024 – Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying frequencies […]
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights. EXTON, PA., May 9, 2024 – Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has remained relatively stagnant. Yet, neurologists […]
Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S. were receiving the amyloid-busting antibody […]
How Do Companies Avert Further Frustration Among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the daunting responsibility of informing patients and caregivers that not […]
